Chymostatin as a therapeutic agent of aspergillosis in murine model
Abstract The purpose of this study was to evaluate the therapeutic effect of chymostatin, as an elastase inhibitor, in mice with invasive aspergillosis. Two Aspergillus fumigatus (A. fumigatus) isolates obtained from animals (bovine mastitis and avian endophthalmitis) along with elastase-producing A...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Omran, Saeed Mahdavi [verfasserIn] Khosravi, Ali Reza [verfasserIn] Shokri, Hojjatollah [verfasserIn] Salehnia, Mohammad [verfasserIn] Lotfi, Ali [verfasserIn] Hajiahmadi, Mahmoud [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2012 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: Comparative haematology international - London : Springer, 1991, 23(2012), 1 vom: 21. Juli, Seite 1-5 |
|---|---|
| Übergeordnetes Werk: |
volume:23 ; year:2012 ; number:1 ; day:21 ; month:07 ; pages:1-5 |
| Links: |
|---|
| DOI / URN: |
10.1007/s00580-012-1559-6 |
|---|
| Katalog-ID: |
SPR007223803 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR007223803 | ||
| 003 | DE-627 | ||
| 005 | 20230519204813.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201005s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00580-012-1559-6 |2 doi | |
| 035 | |a (DE-627)SPR007223803 | ||
| 035 | |a (SPR)s00580-012-1559-6-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 082 | 0 | 4 | |a 610 |q ASE |
| 100 | 1 | |a Omran, Saeed Mahdavi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Chymostatin as a therapeutic agent of aspergillosis in murine model |
| 264 | 1 | |c 2012 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract The purpose of this study was to evaluate the therapeutic effect of chymostatin, as an elastase inhibitor, in mice with invasive aspergillosis. Two Aspergillus fumigatus (A. fumigatus) isolates obtained from animals (bovine mastitis and avian endophthalmitis) along with elastase-producing A. fumigatus ATCC 26933 were inoculated to seven mice groups according to the protocol. The induction of aspergillosis was confirmed by tissue cultures as well as histopathological examination. Chymostatin, as an elastase inhibitor, was used in treating the infected animals at doses of 50, 100, and 200 μM in four different times. There was no mortality in mice group 6 (mice treated with elastase-producing A. fumigatus ATCC 26933 + 200 μM chymostatin). The mortality rate was calculated approximately 50 % in mice infected with elastase-producing A. fumigatus (group 2). The highest colony forming units was observed in the kidney (35.3 %) and the lowest in the liver (5.9 %). Moreover, Aspergillus hyphae were observed in different tissues obtained from died mice in all groups except group 6. The results showed that chymostatin at a dose of 200 μM could be useful as a feasible replacement agent for the treatment of invasive aspergillosis. | ||
| 650 | 4 | |a Chymostatin |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Elastase inhibitor |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Aspergillosis |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Khosravi, Ali Reza |e verfasserin |4 aut | |
| 700 | 1 | |a Shokri, Hojjatollah |e verfasserin |4 aut | |
| 700 | 1 | |a Salehnia, Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Lotfi, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Hajiahmadi, Mahmoud |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Comparative haematology international |d London : Springer, 1991 |g 23(2012), 1 vom: 21. Juli, Seite 1-5 |w (DE-627)559430590 |w (DE-600)2413027-8 |x 1433-2973 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2012 |g number:1 |g day:21 |g month:07 |g pages:1-5 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00580-012-1559-6 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_90 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_100 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_120 | ||
| 912 | |a GBV_ILN_152 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_171 | ||
| 912 | |a GBV_ILN_187 | ||
| 912 | |a GBV_ILN_224 | ||
| 912 | |a GBV_ILN_250 | ||
| 912 | |a GBV_ILN_281 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_370 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_702 | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2012 |e 1 |b 21 |c 07 |h 1-5 | ||
| author_variant |
s m o sm smo a r k ar ark h s hs m s ms a l al m h mh |
|---|---|
| matchkey_str |
article:14332973:2012----::hmsaiaahrpuiaetfseglo |
| hierarchy_sort_str |
2012 |
| publishDate |
2012 |
| allfields |
10.1007/s00580-012-1559-6 doi (DE-627)SPR007223803 (SPR)s00580-012-1559-6-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE Omran, Saeed Mahdavi verfasserin aut Chymostatin as a therapeutic agent of aspergillosis in murine model 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract The purpose of this study was to evaluate the therapeutic effect of chymostatin, as an elastase inhibitor, in mice with invasive aspergillosis. Two Aspergillus fumigatus (A. fumigatus) isolates obtained from animals (bovine mastitis and avian endophthalmitis) along with elastase-producing A. fumigatus ATCC 26933 were inoculated to seven mice groups according to the protocol. The induction of aspergillosis was confirmed by tissue cultures as well as histopathological examination. Chymostatin, as an elastase inhibitor, was used in treating the infected animals at doses of 50, 100, and 200 μM in four different times. There was no mortality in mice group 6 (mice treated with elastase-producing A. fumigatus ATCC 26933 + 200 μM chymostatin). The mortality rate was calculated approximately 50 % in mice infected with elastase-producing A. fumigatus (group 2). The highest colony forming units was observed in the kidney (35.3 %) and the lowest in the liver (5.9 %). Moreover, Aspergillus hyphae were observed in different tissues obtained from died mice in all groups except group 6. The results showed that chymostatin at a dose of 200 μM could be useful as a feasible replacement agent for the treatment of invasive aspergillosis. Chymostatin (dpeaa)DE-He213 Elastase inhibitor (dpeaa)DE-He213 Aspergillosis (dpeaa)DE-He213 Khosravi, Ali Reza verfasserin aut Shokri, Hojjatollah verfasserin aut Salehnia, Mohammad verfasserin aut Lotfi, Ali verfasserin aut Hajiahmadi, Mahmoud verfasserin aut Enthalten in Comparative haematology international London : Springer, 1991 23(2012), 1 vom: 21. Juli, Seite 1-5 (DE-627)559430590 (DE-600)2413027-8 1433-2973 nnns volume:23 year:2012 number:1 day:21 month:07 pages:1-5 https://dx.doi.org/10.1007/s00580-012-1559-6 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 23 2012 1 21 07 1-5 |
| spelling |
10.1007/s00580-012-1559-6 doi (DE-627)SPR007223803 (SPR)s00580-012-1559-6-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE Omran, Saeed Mahdavi verfasserin aut Chymostatin as a therapeutic agent of aspergillosis in murine model 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract The purpose of this study was to evaluate the therapeutic effect of chymostatin, as an elastase inhibitor, in mice with invasive aspergillosis. Two Aspergillus fumigatus (A. fumigatus) isolates obtained from animals (bovine mastitis and avian endophthalmitis) along with elastase-producing A. fumigatus ATCC 26933 were inoculated to seven mice groups according to the protocol. The induction of aspergillosis was confirmed by tissue cultures as well as histopathological examination. Chymostatin, as an elastase inhibitor, was used in treating the infected animals at doses of 50, 100, and 200 μM in four different times. There was no mortality in mice group 6 (mice treated with elastase-producing A. fumigatus ATCC 26933 + 200 μM chymostatin). The mortality rate was calculated approximately 50 % in mice infected with elastase-producing A. fumigatus (group 2). The highest colony forming units was observed in the kidney (35.3 %) and the lowest in the liver (5.9 %). Moreover, Aspergillus hyphae were observed in different tissues obtained from died mice in all groups except group 6. The results showed that chymostatin at a dose of 200 μM could be useful as a feasible replacement agent for the treatment of invasive aspergillosis. Chymostatin (dpeaa)DE-He213 Elastase inhibitor (dpeaa)DE-He213 Aspergillosis (dpeaa)DE-He213 Khosravi, Ali Reza verfasserin aut Shokri, Hojjatollah verfasserin aut Salehnia, Mohammad verfasserin aut Lotfi, Ali verfasserin aut Hajiahmadi, Mahmoud verfasserin aut Enthalten in Comparative haematology international London : Springer, 1991 23(2012), 1 vom: 21. Juli, Seite 1-5 (DE-627)559430590 (DE-600)2413027-8 1433-2973 nnns volume:23 year:2012 number:1 day:21 month:07 pages:1-5 https://dx.doi.org/10.1007/s00580-012-1559-6 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 23 2012 1 21 07 1-5 |
| allfields_unstemmed |
10.1007/s00580-012-1559-6 doi (DE-627)SPR007223803 (SPR)s00580-012-1559-6-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE Omran, Saeed Mahdavi verfasserin aut Chymostatin as a therapeutic agent of aspergillosis in murine model 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract The purpose of this study was to evaluate the therapeutic effect of chymostatin, as an elastase inhibitor, in mice with invasive aspergillosis. Two Aspergillus fumigatus (A. fumigatus) isolates obtained from animals (bovine mastitis and avian endophthalmitis) along with elastase-producing A. fumigatus ATCC 26933 were inoculated to seven mice groups according to the protocol. The induction of aspergillosis was confirmed by tissue cultures as well as histopathological examination. Chymostatin, as an elastase inhibitor, was used in treating the infected animals at doses of 50, 100, and 200 μM in four different times. There was no mortality in mice group 6 (mice treated with elastase-producing A. fumigatus ATCC 26933 + 200 μM chymostatin). The mortality rate was calculated approximately 50 % in mice infected with elastase-producing A. fumigatus (group 2). The highest colony forming units was observed in the kidney (35.3 %) and the lowest in the liver (5.9 %). Moreover, Aspergillus hyphae were observed in different tissues obtained from died mice in all groups except group 6. The results showed that chymostatin at a dose of 200 μM could be useful as a feasible replacement agent for the treatment of invasive aspergillosis. Chymostatin (dpeaa)DE-He213 Elastase inhibitor (dpeaa)DE-He213 Aspergillosis (dpeaa)DE-He213 Khosravi, Ali Reza verfasserin aut Shokri, Hojjatollah verfasserin aut Salehnia, Mohammad verfasserin aut Lotfi, Ali verfasserin aut Hajiahmadi, Mahmoud verfasserin aut Enthalten in Comparative haematology international London : Springer, 1991 23(2012), 1 vom: 21. Juli, Seite 1-5 (DE-627)559430590 (DE-600)2413027-8 1433-2973 nnns volume:23 year:2012 number:1 day:21 month:07 pages:1-5 https://dx.doi.org/10.1007/s00580-012-1559-6 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 23 2012 1 21 07 1-5 |
| allfieldsGer |
10.1007/s00580-012-1559-6 doi (DE-627)SPR007223803 (SPR)s00580-012-1559-6-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE Omran, Saeed Mahdavi verfasserin aut Chymostatin as a therapeutic agent of aspergillosis in murine model 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract The purpose of this study was to evaluate the therapeutic effect of chymostatin, as an elastase inhibitor, in mice with invasive aspergillosis. Two Aspergillus fumigatus (A. fumigatus) isolates obtained from animals (bovine mastitis and avian endophthalmitis) along with elastase-producing A. fumigatus ATCC 26933 were inoculated to seven mice groups according to the protocol. The induction of aspergillosis was confirmed by tissue cultures as well as histopathological examination. Chymostatin, as an elastase inhibitor, was used in treating the infected animals at doses of 50, 100, and 200 μM in four different times. There was no mortality in mice group 6 (mice treated with elastase-producing A. fumigatus ATCC 26933 + 200 μM chymostatin). The mortality rate was calculated approximately 50 % in mice infected with elastase-producing A. fumigatus (group 2). The highest colony forming units was observed in the kidney (35.3 %) and the lowest in the liver (5.9 %). Moreover, Aspergillus hyphae were observed in different tissues obtained from died mice in all groups except group 6. The results showed that chymostatin at a dose of 200 μM could be useful as a feasible replacement agent for the treatment of invasive aspergillosis. Chymostatin (dpeaa)DE-He213 Elastase inhibitor (dpeaa)DE-He213 Aspergillosis (dpeaa)DE-He213 Khosravi, Ali Reza verfasserin aut Shokri, Hojjatollah verfasserin aut Salehnia, Mohammad verfasserin aut Lotfi, Ali verfasserin aut Hajiahmadi, Mahmoud verfasserin aut Enthalten in Comparative haematology international London : Springer, 1991 23(2012), 1 vom: 21. Juli, Seite 1-5 (DE-627)559430590 (DE-600)2413027-8 1433-2973 nnns volume:23 year:2012 number:1 day:21 month:07 pages:1-5 https://dx.doi.org/10.1007/s00580-012-1559-6 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 23 2012 1 21 07 1-5 |
| allfieldsSound |
10.1007/s00580-012-1559-6 doi (DE-627)SPR007223803 (SPR)s00580-012-1559-6-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE Omran, Saeed Mahdavi verfasserin aut Chymostatin as a therapeutic agent of aspergillosis in murine model 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract The purpose of this study was to evaluate the therapeutic effect of chymostatin, as an elastase inhibitor, in mice with invasive aspergillosis. Two Aspergillus fumigatus (A. fumigatus) isolates obtained from animals (bovine mastitis and avian endophthalmitis) along with elastase-producing A. fumigatus ATCC 26933 were inoculated to seven mice groups according to the protocol. The induction of aspergillosis was confirmed by tissue cultures as well as histopathological examination. Chymostatin, as an elastase inhibitor, was used in treating the infected animals at doses of 50, 100, and 200 μM in four different times. There was no mortality in mice group 6 (mice treated with elastase-producing A. fumigatus ATCC 26933 + 200 μM chymostatin). The mortality rate was calculated approximately 50 % in mice infected with elastase-producing A. fumigatus (group 2). The highest colony forming units was observed in the kidney (35.3 %) and the lowest in the liver (5.9 %). Moreover, Aspergillus hyphae were observed in different tissues obtained from died mice in all groups except group 6. The results showed that chymostatin at a dose of 200 μM could be useful as a feasible replacement agent for the treatment of invasive aspergillosis. Chymostatin (dpeaa)DE-He213 Elastase inhibitor (dpeaa)DE-He213 Aspergillosis (dpeaa)DE-He213 Khosravi, Ali Reza verfasserin aut Shokri, Hojjatollah verfasserin aut Salehnia, Mohammad verfasserin aut Lotfi, Ali verfasserin aut Hajiahmadi, Mahmoud verfasserin aut Enthalten in Comparative haematology international London : Springer, 1991 23(2012), 1 vom: 21. Juli, Seite 1-5 (DE-627)559430590 (DE-600)2413027-8 1433-2973 nnns volume:23 year:2012 number:1 day:21 month:07 pages:1-5 https://dx.doi.org/10.1007/s00580-012-1559-6 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 23 2012 1 21 07 1-5 |
| language |
English |
| source |
Enthalten in Comparative haematology international 23(2012), 1 vom: 21. Juli, Seite 1-5 volume:23 year:2012 number:1 day:21 month:07 pages:1-5 |
| sourceStr |
Enthalten in Comparative haematology international 23(2012), 1 vom: 21. Juli, Seite 1-5 volume:23 year:2012 number:1 day:21 month:07 pages:1-5 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Chymostatin Elastase inhibitor Aspergillosis |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Comparative haematology international |
| authorswithroles_txt_mv |
Omran, Saeed Mahdavi @@aut@@ Khosravi, Ali Reza @@aut@@ Shokri, Hojjatollah @@aut@@ Salehnia, Mohammad @@aut@@ Lotfi, Ali @@aut@@ Hajiahmadi, Mahmoud @@aut@@ |
| publishDateDaySort_date |
2012-07-21T00:00:00Z |
| hierarchy_top_id |
559430590 |
| dewey-sort |
3610 |
| id |
SPR007223803 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR007223803</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519204813.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201005s2012 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s00580-012-1559-6</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR007223803</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s00580-012-1559-6-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Omran, Saeed Mahdavi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Chymostatin as a therapeutic agent of aspergillosis in murine model</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2012</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract The purpose of this study was to evaluate the therapeutic effect of chymostatin, as an elastase inhibitor, in mice with invasive aspergillosis. Two Aspergillus fumigatus (A. fumigatus) isolates obtained from animals (bovine mastitis and avian endophthalmitis) along with elastase-producing A. fumigatus ATCC 26933 were inoculated to seven mice groups according to the protocol. The induction of aspergillosis was confirmed by tissue cultures as well as histopathological examination. Chymostatin, as an elastase inhibitor, was used in treating the infected animals at doses of 50, 100, and 200 μM in four different times. There was no mortality in mice group 6 (mice treated with elastase-producing A. fumigatus ATCC 26933 + 200 μM chymostatin). The mortality rate was calculated approximately 50 % in mice infected with elastase-producing A. fumigatus (group 2). The highest colony forming units was observed in the kidney (35.3 %) and the lowest in the liver (5.9 %). Moreover, Aspergillus hyphae were observed in different tissues obtained from died mice in all groups except group 6. The results showed that chymostatin at a dose of 200 μM could be useful as a feasible replacement agent for the treatment of invasive aspergillosis.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Chymostatin</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Elastase inhibitor</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Aspergillosis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Khosravi, Ali Reza</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shokri, Hojjatollah</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Salehnia, Mohammad</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lotfi, Ali</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hajiahmadi, Mahmoud</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Comparative haematology international</subfield><subfield code="d">London : Springer, 1991</subfield><subfield code="g">23(2012), 1 vom: 21. Juli, Seite 1-5</subfield><subfield code="w">(DE-627)559430590</subfield><subfield code="w">(DE-600)2413027-8</subfield><subfield code="x">1433-2973</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:23</subfield><subfield code="g">year:2012</subfield><subfield code="g">number:1</subfield><subfield code="g">day:21</subfield><subfield code="g">month:07</subfield><subfield code="g">pages:1-5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s00580-012-1559-6</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">23</subfield><subfield code="j">2012</subfield><subfield code="e">1</subfield><subfield code="b">21</subfield><subfield code="c">07</subfield><subfield code="h">1-5</subfield></datafield></record></collection>
|
| author |
Omran, Saeed Mahdavi |
| spellingShingle |
Omran, Saeed Mahdavi ddc 610 misc Chymostatin misc Elastase inhibitor misc Aspergillosis Chymostatin as a therapeutic agent of aspergillosis in murine model |
| authorStr |
Omran, Saeed Mahdavi |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)559430590 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1433-2973 |
| topic_title |
610 ASE Chymostatin as a therapeutic agent of aspergillosis in murine model Chymostatin (dpeaa)DE-He213 Elastase inhibitor (dpeaa)DE-He213 Aspergillosis (dpeaa)DE-He213 |
| topic |
ddc 610 misc Chymostatin misc Elastase inhibitor misc Aspergillosis |
| topic_unstemmed |
ddc 610 misc Chymostatin misc Elastase inhibitor misc Aspergillosis |
| topic_browse |
ddc 610 misc Chymostatin misc Elastase inhibitor misc Aspergillosis |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Comparative haematology international |
| hierarchy_parent_id |
559430590 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Comparative haematology international |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)559430590 (DE-600)2413027-8 |
| title |
Chymostatin as a therapeutic agent of aspergillosis in murine model |
| ctrlnum |
(DE-627)SPR007223803 (SPR)s00580-012-1559-6-e |
| title_full |
Chymostatin as a therapeutic agent of aspergillosis in murine model |
| author_sort |
Omran, Saeed Mahdavi |
| journal |
Comparative haematology international |
| journalStr |
Comparative haematology international |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2012 |
| contenttype_str_mv |
txt |
| container_start_page |
1 |
| author_browse |
Omran, Saeed Mahdavi Khosravi, Ali Reza Shokri, Hojjatollah Salehnia, Mohammad Lotfi, Ali Hajiahmadi, Mahmoud |
| container_volume |
23 |
| class |
610 ASE |
| format_se |
Elektronische Aufsätze |
| author-letter |
Omran, Saeed Mahdavi |
| doi_str_mv |
10.1007/s00580-012-1559-6 |
| dewey-full |
610 |
| author2-role |
verfasserin |
| title_sort |
chymostatin as a therapeutic agent of aspergillosis in murine model |
| title_auth |
Chymostatin as a therapeutic agent of aspergillosis in murine model |
| abstract |
Abstract The purpose of this study was to evaluate the therapeutic effect of chymostatin, as an elastase inhibitor, in mice with invasive aspergillosis. Two Aspergillus fumigatus (A. fumigatus) isolates obtained from animals (bovine mastitis and avian endophthalmitis) along with elastase-producing A. fumigatus ATCC 26933 were inoculated to seven mice groups according to the protocol. The induction of aspergillosis was confirmed by tissue cultures as well as histopathological examination. Chymostatin, as an elastase inhibitor, was used in treating the infected animals at doses of 50, 100, and 200 μM in four different times. There was no mortality in mice group 6 (mice treated with elastase-producing A. fumigatus ATCC 26933 + 200 μM chymostatin). The mortality rate was calculated approximately 50 % in mice infected with elastase-producing A. fumigatus (group 2). The highest colony forming units was observed in the kidney (35.3 %) and the lowest in the liver (5.9 %). Moreover, Aspergillus hyphae were observed in different tissues obtained from died mice in all groups except group 6. The results showed that chymostatin at a dose of 200 μM could be useful as a feasible replacement agent for the treatment of invasive aspergillosis. |
| abstractGer |
Abstract The purpose of this study was to evaluate the therapeutic effect of chymostatin, as an elastase inhibitor, in mice with invasive aspergillosis. Two Aspergillus fumigatus (A. fumigatus) isolates obtained from animals (bovine mastitis and avian endophthalmitis) along with elastase-producing A. fumigatus ATCC 26933 were inoculated to seven mice groups according to the protocol. The induction of aspergillosis was confirmed by tissue cultures as well as histopathological examination. Chymostatin, as an elastase inhibitor, was used in treating the infected animals at doses of 50, 100, and 200 μM in four different times. There was no mortality in mice group 6 (mice treated with elastase-producing A. fumigatus ATCC 26933 + 200 μM chymostatin). The mortality rate was calculated approximately 50 % in mice infected with elastase-producing A. fumigatus (group 2). The highest colony forming units was observed in the kidney (35.3 %) and the lowest in the liver (5.9 %). Moreover, Aspergillus hyphae were observed in different tissues obtained from died mice in all groups except group 6. The results showed that chymostatin at a dose of 200 μM could be useful as a feasible replacement agent for the treatment of invasive aspergillosis. |
| abstract_unstemmed |
Abstract The purpose of this study was to evaluate the therapeutic effect of chymostatin, as an elastase inhibitor, in mice with invasive aspergillosis. Two Aspergillus fumigatus (A. fumigatus) isolates obtained from animals (bovine mastitis and avian endophthalmitis) along with elastase-producing A. fumigatus ATCC 26933 were inoculated to seven mice groups according to the protocol. The induction of aspergillosis was confirmed by tissue cultures as well as histopathological examination. Chymostatin, as an elastase inhibitor, was used in treating the infected animals at doses of 50, 100, and 200 μM in four different times. There was no mortality in mice group 6 (mice treated with elastase-producing A. fumigatus ATCC 26933 + 200 μM chymostatin). The mortality rate was calculated approximately 50 % in mice infected with elastase-producing A. fumigatus (group 2). The highest colony forming units was observed in the kidney (35.3 %) and the lowest in the liver (5.9 %). Moreover, Aspergillus hyphae were observed in different tissues obtained from died mice in all groups except group 6. The results showed that chymostatin at a dose of 200 μM could be useful as a feasible replacement agent for the treatment of invasive aspergillosis. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 |
| container_issue |
1 |
| title_short |
Chymostatin as a therapeutic agent of aspergillosis in murine model |
| url |
https://dx.doi.org/10.1007/s00580-012-1559-6 |
| remote_bool |
true |
| author2 |
Khosravi, Ali Reza Shokri, Hojjatollah Salehnia, Mohammad Lotfi, Ali Hajiahmadi, Mahmoud |
| author2Str |
Khosravi, Ali Reza Shokri, Hojjatollah Salehnia, Mohammad Lotfi, Ali Hajiahmadi, Mahmoud |
| ppnlink |
559430590 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s00580-012-1559-6 |
| up_date |
2024-07-04T02:29:02.193Z |
| _version_ |
1803613783663312896 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR007223803</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519204813.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201005s2012 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s00580-012-1559-6</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR007223803</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s00580-012-1559-6-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Omran, Saeed Mahdavi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Chymostatin as a therapeutic agent of aspergillosis in murine model</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2012</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract The purpose of this study was to evaluate the therapeutic effect of chymostatin, as an elastase inhibitor, in mice with invasive aspergillosis. Two Aspergillus fumigatus (A. fumigatus) isolates obtained from animals (bovine mastitis and avian endophthalmitis) along with elastase-producing A. fumigatus ATCC 26933 were inoculated to seven mice groups according to the protocol. The induction of aspergillosis was confirmed by tissue cultures as well as histopathological examination. Chymostatin, as an elastase inhibitor, was used in treating the infected animals at doses of 50, 100, and 200 μM in four different times. There was no mortality in mice group 6 (mice treated with elastase-producing A. fumigatus ATCC 26933 + 200 μM chymostatin). The mortality rate was calculated approximately 50 % in mice infected with elastase-producing A. fumigatus (group 2). The highest colony forming units was observed in the kidney (35.3 %) and the lowest in the liver (5.9 %). Moreover, Aspergillus hyphae were observed in different tissues obtained from died mice in all groups except group 6. The results showed that chymostatin at a dose of 200 μM could be useful as a feasible replacement agent for the treatment of invasive aspergillosis.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Chymostatin</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Elastase inhibitor</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Aspergillosis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Khosravi, Ali Reza</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shokri, Hojjatollah</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Salehnia, Mohammad</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lotfi, Ali</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hajiahmadi, Mahmoud</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Comparative haematology international</subfield><subfield code="d">London : Springer, 1991</subfield><subfield code="g">23(2012), 1 vom: 21. Juli, Seite 1-5</subfield><subfield code="w">(DE-627)559430590</subfield><subfield code="w">(DE-600)2413027-8</subfield><subfield code="x">1433-2973</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:23</subfield><subfield code="g">year:2012</subfield><subfield code="g">number:1</subfield><subfield code="g">day:21</subfield><subfield code="g">month:07</subfield><subfield code="g">pages:1-5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s00580-012-1559-6</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">23</subfield><subfield code="j">2012</subfield><subfield code="e">1</subfield><subfield code="b">21</subfield><subfield code="c">07</subfield><subfield code="h">1-5</subfield></datafield></record></collection>
|
| score |
7.4005013 |